These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 31363161)

  • 1. A prospective evaluation of pegylated interferon alfa-2a therapy in patients with polycythemia vera and essential thrombocythemia with a prior splanchnic vein thrombosis.
    Mascarenhas J; Kosiorek H; Prchal J; Yacoub A; Berenzon D; Baer MR; Ritchie E; Silver RT; Kessler C; Winton E; Finazzi MC; Rambaldi A; Vannucchi AM; Leibowitz D; Rondelli D; Arcasoy MO; Catchatourian R; Vadakara J; Rosti V; Hexner E; Kremyanskaya M; Sandy L; Tripodi J; Najfeld V; Farnoud N; Salama ME; Weinberg RS; Rampal R; Goldberg JD; Mesa R; Dueck AC; Hoffman R
    Leukemia; 2019 Dec; 33(12):2974-2978. PubMed ID: 31363161
    [No Abstract]   [Full Text] [Related]  

  • 2. Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trial.
    Masarova L; Patel KP; Newberry KJ; Cortes J; Borthakur G; Konopleva M; Estrov Z; Kantarjian H; Verstovsek S
    Lancet Haematol; 2017 Apr; 4(4):e165-e175. PubMed ID: 28291640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cepeginterferon alfa-2b in the treatment of chronic myeloproliferative diseases.
    Melikyan AL; Subortseva IN; Gilyazitdinova EA; Koloshejnova TI; Pustovaya EI; Egorova EK; Kovrigina AM; Sudarikov AB; Abdullaev AO; Lomaia EG; Siordiya NT; Zaritskey AY; Savchenko VG
    Ter Arkh; 2018 Aug; 90(7):23-29. PubMed ID: 30701919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera.
    Quintás-Cardama A; Kantarjian H; Manshouri T; Luthra R; Estrov Z; Pierce S; Richie MA; Borthakur G; Konopleva M; Cortes J; Verstovsek S
    J Clin Oncol; 2009 Nov; 27(32):5418-24. PubMed ID: 19826111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pegylated interferon alpha - 2a is clinically effective and tolerable in myeloproliferative neoplasm patients treated off clinical trial.
    Gowin K; Jain T; Kosiorek H; Tibes R; Camoriano J; Palmer J; Mesa R
    Leuk Res; 2017 Mar; 54():73-77. PubMed ID: 28113109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of pegylated interferon in young patients with polycythemia vera and essential thrombocythemia.
    Kucine N; Bergmann S; Krichevsky S; Jones D; Rytting M; Jain J; Bennett CM; Resar LMS; Mascarenhas J; Verstovsek S; Hoffman R
    Pediatr Blood Cancer; 2021 Mar; 68(3):e28888. PubMed ID: 33381905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea.
    Yacoub A; Mascarenhas J; Kosiorek H; Prchal JT; Berenzon D; Baer MR; Ritchie E; Silver RT; Kessler C; Winton E; Finazzi MC; Rambaldi A; Vannucchi AM; Leibowitz D; Rondelli D; Arcasoy MO; Catchatourian R; Vadakara J; Rosti V; Hexner E; Kremyanskaya M; Sandy L; Tripodi J; Najfeld V; Farnoud N; Papaemmanuil E; Salama M; Singer-Weinberg R; Rampal R; Goldberg JD; Barbui T; Mesa R; Dueck AC; Hoffman R
    Blood; 2019 Oct; 134(18):1498-1509. PubMed ID: 31515250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pegylated interferon alpha-2a for essential thrombocythemia during pregnancy: outcome and safety. A case series.
    Beauverd Y; Radia D; Cargo C; Knapper S; Drummond M; Pillai A; Harrison C; Robinson S
    Haematologica; 2016 May; 101(5):e182-4. PubMed ID: 26819057
    [No Abstract]   [Full Text] [Related]  

  • 9. Ropeginterferon alfa-2b for the treatment of patients with polycythemia vera.
    Wagner SM; Melchardt T; Greil R
    Drugs Today (Barc); 2020 Mar; 56(3):195-202. PubMed ID: 32282866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pegylated interferon Alfa-2a and hydroxyurea in polycythemia vera and essential thrombocythemia: differential cellular and molecular responses.
    Tashi T; Swierczek S; Kim SJ; Salama ME; Song J; Heikal N; King KY; Hickman K; Litton S; Prchal JT
    Leukemia; 2018 Aug; 32(8):1830-1833. PubMed ID: 29556018
    [No Abstract]   [Full Text] [Related]  

  • 11. Symptom burden and quality of life in patients with high-risk essential thrombocythaemia and polycythaemia vera receiving hydroxyurea or pegylated interferon alfa-2a: a post-hoc analysis of the MPN-RC 111 and 112 trials.
    Mazza GL; Mead-Harvey C; Mascarenhas J; Yacoub A; Kosiorek HE; Hoffman R; Dueck AC; Mesa RA;
    Lancet Haematol; 2022 Jan; 9(1):e38-e48. PubMed ID: 34971581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Essential thrombocythaemia treated with recombinant interferon: 'real world' United Kingdom referral centre experience.
    Desterro J; McLornan DP; Curto Garcia N; O'Sullivan J; Alimam S; Keohane C; Woodley C; Francis Y; Kordasti S; Radia DH; Harrison CN
    Br J Haematol; 2019 Aug; 186(4):561-564. PubMed ID: 31090926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanism of Action of Ropeginterferon Alfa-2b in Polycythemia Vera Treatment.
    Qin A
    Clin Ther; 2024 May; 46(5):439-440. PubMed ID: 38697872
    [No Abstract]   [Full Text] [Related]  

  • 14. Natural history of polycythemia vera and essential thrombocythemia presenting with splanchnic vein thrombosis.
    Alvarez-Larrán A; Pereira A; Magaz M; Hernández-Boluda JC; Garrote M; Cuevas B; Ferrer-Marín F; Gómez-Casares MT; García-Gutiérrez V; Mata-Vázquez MI; Turon F; Hernandez-Gea V; Arellano-Rodrigo E; Cervantes F; García-Pagán JC;
    Ann Hematol; 2020 Apr; 99(4):791-798. PubMed ID: 32086587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of thrombosis in polycythemia vera and essential thrombocythemia.
    Landolfi R; Di Gennaro L
    Haematologica; 2008 Mar; 93(3):331-5. PubMed ID: 18310537
    [No Abstract]   [Full Text] [Related]  

  • 16. ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options.
    Kiladjian JJ; Marin FF; Al-Ali HK; Alvarez-Larrán A; Beggiato E; Bieniaszewska M; Breccia M; Buxhofer-Ausch V; Cerna O; Crisan AM; Danaila CD; De Stefano V; Döhner K; Empson V; Gora-Tybor J; Griesshammer M; Grosicki S; Guglielmelli P; García-Gutierrez V; Heidel FH; Illés A; Tomuleasa C; James C; Koschmieder S; Krauth MT; Krejcy K; Lazaroiu MC; Mayer J; Nagy ZG; Nicolini FE; Palandri F; Pappa V; Reiter AJ; Sacha T; Schlager S; Schmidt S; Terpos E; Unger M; Wölfler A; Cirici BX; Klade C
    Ann Hematol; 2024 Jul; 103(7):2299-2310. PubMed ID: 38438627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Data-driven analysis of JAK2V617F kinetics during interferon-alpha2 treatment of patients with polycythemia vera and related neoplasms.
    Pedersen RK; Andersen M; Knudsen TA; Sajid Z; Gudmand-Hoeyer J; Dam MJB; Skov V; Kjaer L; Ellervik C; Larsen TS; Hansen D; Pallisgaard N; Hasselbalch HC; Ottesen JT
    Cancer Med; 2020 Mar; 9(6):2039-2051. PubMed ID: 31991066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concurrent polycythemia vera and chronic lymphocytic leukemia: treatment response to pegylated interferon alpha 2a.
    Selinger HA; Ballesteros E; Bona R
    Am J Hematol; 2013 Jun; 88(6):535-6. PubMed ID: 23553722
    [No Abstract]   [Full Text] [Related]  

  • 19. Contemporary approach to essential thrombocythemia and polycythemia vera.
    Aruch D; Mascarenhas J
    Curr Opin Hematol; 2016 Mar; 23(2):150-60. PubMed ID: 26717193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Experience with pegylated interferon α-2a in advanced myeloproliferative neoplasms in an international cohort of 118 patients.
    Gowin K; Thapaliya P; Samuelson J; Harrison C; Radia D; Andreasson B; Mascarenhas J; Rambaldi A; Barbui T; Rea CJ; Camoriano J; Gentry A; Kiladjian JJ; O'Connell C; Mesa R
    Haematologica; 2012 Oct; 97(10):1570-3. PubMed ID: 22419578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.